Cargando…

Indomethacin sensitizes resistant transformed cells to macrophage cytotoxicity

Activated macrophages are well known to exhibit anti-tumor properties. However, certain cell types show intrinsic resistance. Searching for a mechanism that could explain this phenomenon, we observed that the supernatant of resistant cells could confer resistance to otherwise sensitive tumor cells,...

Descripción completa

Detalles Bibliográficos
Autores principales: Totary-Jain, Hana, Sionov, Ronit Vogt, Gallily, Ruth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6011832/
https://www.ncbi.nlm.nih.gov/pubmed/27210423
http://dx.doi.org/10.1016/j.imlet.2016.05.011
Descripción
Sumario:Activated macrophages are well known to exhibit anti-tumor properties. However, certain cell types show intrinsic resistance. Searching for a mechanism that could explain this phenomenon, we observed that the supernatant of resistant cells could confer resistance to otherwise sensitive tumor cells, suggesting the presence of a secreted suppressor factor. The effect was abolished upon dialysis, indicating that the suppressor factor has a low molecular weight. Further studies showed that prostaglandin E(2) (PGE(2)) is secreted by the resistant tumor cells and that inhibition of PGE(2) production by indomethacin, a cyclooxygenase (COX) inhibitor, eliminated the macrophage suppression factor from the supernatant, and sensitized the resistant tumor cells to macrophage cytotoxicity. This study emphasizes the important role of tumor-secreted PGE(2) in escaping macrophage surveillance and justifies the use of COX inhibitors as an adjuvant for improving tumor immunotherapy.